



18 September 2025

To National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Scrip Symbol: SAILIFE	To BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai - 400001 Scrip Code: 544306
--	---

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Dear Sir/ Madam,

In continuation to the disclosure made in the prospectus of the initial public offering (Pg. No. 198 - "Facilities and Approvals") and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") this is to inform you that the Company has successfully opened Unit VI, a dedicated facility for veterinary API production, in Bidar, India, located alongside Unit IV, the company's flagship API manufacturing site in Bidar, Karnataka, India ("Unit IV Bidar Facility") on 18th September 2025.

The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, the Company aims to provide efficient and scalable manufacturing solutions to leading global animal health companies.

We request you to take note of the above.

Thank you.

For Sai Life Sciences Limited

Runa Karan
Company Secretary & Compliance Officer
Membership No.: A13721

Encl: As Above

Sai Life Sciences Limited (CIN: L24110TG1999PLC030970)

Corporate office

L4-01 & 02, SLN Terminus, Survey
#133, Gachibowli Miyapur Road,
Gachibowli, Hyderabad – 500032,
Telangana, India.

Registered office

Plot No. DS-7, IKP Knowledge Park, Turkapally
(V), Shameerpet Mandal, Medchal-Malkajgiri
(Dist), Hyderabad -500078, Telangana, India.

Contact us

T: +91 40 6815 6000,
F: +91 40 6815 6199
E: info@sailife.com
W: www.sailife.com



Sai Life Sciences opens dedicated facility for Veterinary APIs in Bidar, India

September 18, 2025, Hyderabad: Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused [Contract Research, Development, and Manufacturing Organization \(CRDMO\)](#), today announced the opening of Unit VI, a dedicated facility for veterinary API production, in Bidar, India. Located alongside Unit IV, the company's flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs.

The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies.

*Making the announcement, **Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences**, said: "This investment strengthens our ability to meet the growing global demand for high-quality veterinary pharmaceuticals while ensuring the highest standards of innovation, efficiency, and sustainability. We are proud to support our innovator partners in their mission of offering reliable solutions that enhance animal well-being."*

The market for veterinary APIs presents a significant growth opportunity, driven by increasing demand for veterinary medicines and advancements in animal healthcare. Sai Life Sciences' investment in this facility aligns with its strategic vision to enhance its offerings in niche, high-value segments of the pharmaceutical industry. With over two decades of manufacturing expertise, Sai Life Sciences has established itself as a trusted partner in API production, known for its advanced process capabilities, operational excellence, and stringent quality standards. The new facility leverages advanced technologies, robust supply chain management, and best-in-class safety practices to ensure reliable and cost-effective manufacturing of animal health APIs.

About Sai Life Sciences:

Sai Life Sciences is a leading integrated contract research, development, and manufacturing organisation (CRDMO). We work with over 300 global innovator pharma and biotech companies to accelerate the discovery, development, and commercialisation of their NCE small molecule programmes. Over the past 26 years, we have served a diverse set of programmes, consistently delivering value based on our quality and responsiveness. We have over 3,400 employees across our facilities in India, UK and USA. <https://www.sailife.com/>

For further information, contact:

Sriram Gopalakrishnan
Vice President, Corporate Communication
Sai Life Sciences Limited
Ph: +91 9121295355
sriram.g@sailife.com